EUVIMEDObjevte EUVIMED
KommentarOpen access · CC BY 4.0

HIV‐associated dysbiosis and immune recovery during antiretroviral therapy

Samuel D Johnson, Siddappa N Byrareddy

Clinical and Translational Discovery · 2022-06 · 2 (2)

DOI: 10.1002/ctd2.58 ↗

At a glance

Kommentar in Clinical and Translational Discovery, published online on 2022-04-28. Written by Samuel D Johnson and 1 co-authors. Institution: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States. Cited 10 times so far (Crossref); 11 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIAID NIH HHS, NINDS NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The microbiomes of people living with HIV (PLWH) are significantly dysregulated with a loss of bacteria diversity and shifts in composition, including increases in pathogenic and decreases in beneficial species. Because of the microbiome's role in modulating health, the effect of this dysbiosis on immune response in PLWH has been a significant concern, mainly because these shifts can persist even after viral suppression during combination antiretroviral therapy (cART). However, due to limitations on sample availability, few studies have been able to provide insights into these microbiome‐immune interactions. Recently, Olivas‐Martínez et al. characterized ileum and caecum mucosa‐associated microbiomes of PLWH based on their level of peripheral CD4+ T‐cell reconstitution following long‐term cART. Their analysis revealed distinct microbiome signatures predictive of recovery. Additionally, differences in markers of gut inflammation and damage between response groups were described, further implicating mucosal disruptions with immune reconstitution. These new data demonstrate an interdependence of microbiome and therapy response, and additional studies are urgently required to fully elucidate this crosstalk and microbiome dynamics from before/after infection and finally, long‐term viral suppression with cART.

Subjects

Author keywords

Antiretroviral TherapyDysbiosisHIVmicrobiome

Authors and institutions

  • Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States.
  • Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States.

Funding

  • NIAID NIH HHS
  • NINDS NIH HHS

Cite

APA

Johnson, S. D., & Byrareddy, S. N. (2022). HIV‐associated dysbiosis and immune recovery during antiretroviral therapy. Clinical and Translational Discovery, 2(2). https://doi.org/10.1002/ctd2.58

Vancouver

Johnson SD, Byrareddy SN. HIV‐associated dysbiosis and immune recovery during antiretroviral therapy. Clinical and Translational Discovery. 2022;2(2). doi:10.1002/ctd2.58

BibTeX
@article{Johnson2022,
  author = {Johnson, Samuel D and Byrareddy, Siddappa N},
  title = {HIV‐associated dysbiosis and immune recovery during antiretroviral therapy},
  journal = {Clinical and Translational Discovery},
  year = {2022},
  volume = {2},
  number = {2},
  doi = {10.1002/ctd2.58}
}
Start for free →